FDA Commissioner Dr. Marty Makary on Streamlining Drug Approvals and Public Health Challenges

FDA Listening Tour and Drug Approval Process

• 💡 Dr. Marty Makary is conducting a listening tour to meet with pharma and biotech CEOs to understand and improve the FDA's processes.
• 🎯 The goal is to address issues like the over 10-year drug development timeline and identify bottlenecks in the approval process.
• 🔑 Communication between FDA scientific teams and companies is highlighted as a critical factor that can save significant time.
• 🚀 The FDA aims to be less of a "black box" by releasing decision letters to provide predictability for drug makers.

Modernizing Regulatory Standards

• ⚠️ Concerns were raised about complete response letters for two drugs, with companies feeling standards changed unexpectedly.
• 🔬 The FDA is working towards standardization and common standards, moving away from outdated requirements like routine animal testing for drugs already approved and used elsewhere.
• 🤖 Artificial intelligence is being utilized as an organizing tool for reviewing massive applications, with a proposed "page limit" concept for predictability.

Addressing Staffing and Expertise

• 💰 While acknowledging criticism about resources, Dr. Makary emphasizes his role in assessing needs rather than simply demanding more money or authority.
• 🧑‍🔬 He assures that scientific reviewers and inspectors have the necessary resources and that there were no layoffs of scientific staff.
• 🌟 The FDA is confident in meeting review targets and potentially setting a record for approvals this year, highlighting the institution's strength and the pride of its scientists.

Leadership and Departures

• 🎓 Dr. Vinay Prasad's departure after three months is discussed; Makary praises his genius and notes his desire to avoid being a distraction due to "smear pieces."
• 👨‍⚕️ George Tidmarsh MD PhD, a drug developer and academic, is identified as the new top drug regulator.

Sarepta Gene Therapy and Rare Diseases

• ⚠️ A temporary hold on Sarepta's gene therapy for non-ambulatory patients was lifted, and the FDA is committed to regulatory flexibility for rare diseases.
• 💡 A new "plausible mechanism pathway" is being developed, potentially reducing the need for extensive studies by relying on computational modeling for safety.

mRNA Technology and Vaccine Injury

• 💉 The FDA is comfortable with mRNA technology's potential for future pathogens, reviewing applications based on data.
• ❓ Dr. Makary acknowledges that "safe" is relative and that vaccine injury reports need appropriate study, with HHS and NIH beginning to look into it.
• 📊 He suggests that better studies are needed to address public concerns and rule out certain theories, while emphasizing the FDA's role in reviewing applications, not commissioning studies.

Crackdown on Kratom Derivative 7-OH

• ⚠️ The FDA is cracking down on 7-OH, a potent synthetic byproduct of the kratom plant, which is an opioid 13 times more potent than oxycodone.
• 🚨 This substance is being sold in vape stores, and the FDA is concerned about rising addiction and has released a report to educate parents and school boards.
• 🌍 The focus is on the synthetic byproduct, not the kratom plant itself, to risk-stratify public health concerns effectively.